James S Lewis 2nd
Overview
Explore the profile of James S Lewis 2nd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Streifel A, Luis K, Nakrani M, Yu D, Sikka M, Varley C, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae438.
PMID: 39130079
Vancomycin and daptomycin are frequently used in outpatient parenteral antimicrobial therapy (OPAT). We analyze health care utilization and cost to the health care system for vancomycin vs daptomycin in the...
2.
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond
Dixon G, Lewis 2nd J, Thompson 3rd G
Expert Opin Drug Metab Toxicol
. 2024 Jul;
20(8):713-718.
PMID: 38957078
Introduction: Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including spp. and echinocandin-resistant spp. Areas Covered: This evaluation will summarize currently available clinical...
3.
Tucker K, Ham Y, Holmer H, McCracken C, Sukerman E, Lewis 2nd J, et al.
Surg Pract Sci
. 2024 Jun;
16():100232.
PMID: 38915860
Background: Beta-lactam antibiotics are first-line agents for most patients receiving antimicrobial prophylaxis in surgical procedures. Despite evidence showing low cross-reactivity between penicillins and cephalosporins, patients with beta-lactam allergies commonly receive...
4.
Streifel A, Strnad L, Sikka M, Varley C, Makadia J, Sukerman E, et al.
Open Forum Infect Dis
. 2024 Mar;
11(3):ofae070.
PMID: 38449918
Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection...
5.
Douglass A, Mayer H, Young K, Sikka M, Strnad L, Makadia J, et al.
Ther Adv Infect Dis
. 2023 Aug;
10:20499361231189405.
PMID: 37581105
Background: Serious infections in persons who use drugs (PWUD) are rising. Dalbavancin, due to its extended half-life, offers an alternative treatment for patients in whom standard of care antibiotics are...
6.
Narayanan N, Lewis 2nd J
Clin Infect Dis
. 2023 Jul;
77(12):1737-1738.
PMID: 37517034
No abstract available.
7.
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson 3rd G, Jenks J, Baddley J, Lewis 2nd J, Egger M, Schwartz I, et al.
Clin Microbiol Rev
. 2023 Jul;
36(3):e0001923.
PMID: 37439685
Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated with high morbidity and mortality (>70%), and presents numerous challenges during clinical care. spp. are the...
8.
Egge S, Lewis 2nd J, Hakki M
Antimicrob Agents Chemother
. 2023 Jul;
67(8):e0066323.
PMID: 37395652
Multidrug-resistant/extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa (PA) are critical antimicrobial resistance threats. Despite their increasing prevalence, treatment options for metallo-β-lactamase (MBL)-producing PA are limited, especially for New Delhi metallo-β-lactamase (NDM) producers....
9.
Simner P, Palavecino E, Satlin M, Mathers A, Weinstein M, Lewis 2nd J, et al.
J Clin Microbiol
. 2023 Mar;
61(4):e0160022.
PMID: 36946754
No abstract available.
10.
McCollam S, Lewis 2nd J, Bubalo J, Diaz A
Antimicrob Agents Chemother
. 2022 Oct;
66(11):e0083322.
PMID: 36214573
The purpose of this single-center retrospective case series was to evaluate the efficacy and safety of 300-mg once-monthly intravenous (IV) pentamidine prophylaxis in 702 adult allogeneic hematopoietic stem cell transplant...